Effect of privatization of the drug distribution system on drug prices in Malaysia

Public Health

Volumn 123, Issue 8, 2009, Pages 523-533

  Babar, Z D ^a   Izham, M I M ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Drug distribution system; Drug prices; International reference prices; Malaysia; Privatization

Indexed keywords

ADRENALIN; ALFACALCIDOL; BCG VACCINE; BENSERAZIDE; BROMOCRIPTINE MESILATE; BUPIVACAINE; CALCIUM LACTATE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CHLORPROMAZINE; DIAZEPAM; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FENTANYL; FLUPHENAZINE DECANOATE; FOLIC ACID; GENERIC DRUG; HALOPERIDOL; HEPATITIS B VACCINE; ISOFLURANE; LEVODOPA; MORPHINE SULFATE; NICOTINAMIDE; PHENYTOIN; POTASSIUM CHLORIDE; PYRITINOL; RHESUS D ANTIBODY; TETANUS TOXOID; THIOPENTAL; UNINDEXED DRUG; VITAMIN B COMPLEX;

DRUG; HEALTH EXPENDITURE; HEALTH SERVICES; MARKET CONDITIONS; PRICE DETERMINATION; PRICING POLICY; PRIVATIZATION;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG MARKETING; GOVERNMENT REGULATION; HEALTH CARE ACCESS; MALAYSIA; ORGANIZATION AND MANAGEMENT; PHARMACY;

DRUG COSTS; DRUG INDUSTRY; DRUGS, ESSENTIAL; DRUGS, GENERIC; GOVERNMENT PROGRAMS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALAYSIA; PHARMACEUTICAL SERVICES; PRIVATE SECTOR; PRIVATIZATION; PUBLIC SECTOR; RETROSPECTIVE STUDIES;

ASIA; EURASIA; MALAYSIA; SOUTHEAST ASIA;

EID: 69849104272     PISSN: 00333506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.puhe.2009.06.011     Document Type: Article

References (51)

1. Sangaralingam M., and Raman M. The high cost of private monopolies, original report (2003). Malaysia. Available at: www.sowatch.org.uy/en/informmesNacionales/351.html [accessed 10.01.05]
2. Shepard S.D., Savedoff W., and Hong P.K. Healthcare reform initiatives in Malaysia. Report of a consultation with the planning and development division (2002), Ministry of Health, Kuala Lumpur. http://www.who.int/health_financing/countries/en/malaysia.pdf Available at:
3. In: Velden K.V.D., Ginneken J.K.S.V., Velema J.P., de Walle F.B., and Winjen J.H.V. (Eds). Health matters: public health in north-south perspective (1995), Royal Tropical Institute, Amsterdam 43-62
4. World Health Organization. World Health Report. Working together for health (2006), WHO, Geneva
5. In: Quick J.D., Rankin J.R., Laing R.O., O'Connor R.W., Hogerzeil H.V., Dukes M.N., et al. (Eds). Managing drug supply. 2nd ed. (1997), Kumarian Press, West Hartford, CT
6. Lek C.S. Health plan to be modeled after Sosco. The Star (14/12/2005)
7. Lyles A. Medical spending increases, but pharmaceuticals pose a paradox. Clin Ther 24 (2002) 300-301
8. Babar Z.U., Ibrahim M., Izham M., and Bukhari N.I. Effect of privatization of drug distribution system on the prices of anti-infectives in Malaysia. J Pharm Finan Econ Pol 13 (2004) 3-26
9. Devaraj K. Healthcare privatization will burden Malaysia. Aliran Month 24 (2004)
10. Babar Z.U., Ibrahim M., Izham M., and Bukhari N.I. A pricing analysis of cardiovascular and blood products after privatization of dug distribution system in Malaysia. J Pharm Finan Econ Pol 14 (2005)
11. Farmasi B. Cost of drugs, Editorial. 1981.
12. Consumer Association of Penang. Consumer Association of Penang memorandum on drug prices in Malaysia - the need for control. Malaysia; 1994.
13. Babar Z.U.D., Ibrahim M.I.M., Singh H., Bukahri N.I., and Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med 4 (2007) e82
14. Ministry of Health. Drug prices in Malaysia (1996), Press Release
15. National Medicine Policy. National medicine policy draft 7 (2003), Pharmaceutical Services Division, Ministry of Health, Malaysia. Available at: www.crc.gov.my/nmus/documents/draf%207%20NMP%20already%20presented%20to% 20mesy%20khas%20kpk.pdf
16. Lek C.S. More than a politician. Med Grapevine (2005) 7-8
17. In: McFadyen J.E. (Ed). International drug price indicator guide 2003 (2004), Management Sciences for Health, Boston
18. Gilman A.G., Hardman J.G., and Limbird L.E. Goodman and Gilman's pharmacological basis of therapeutics. 10th ed. (2001), McGraw Hill, New York
19. Essential drug list. 13th ed. WHO Model List (2003), Department of Essential Drug and Medicine Policy
20. The national health morbidity survey (1996), Ministry of Health, Malaysia
21. Division of Burden of Disease Institute for Public Health. Malaysian burden of disease and injury study. Health prioritization: burden of disease approach (2004), Ministry of Health, Malaysia
22. In: Sarojini S., and Lim T.O. (Eds). Malaysian statistics on medicine 2004 (2006). Kuala Lumpur. Available at: www.crc.gov.my/nmus
23. Babar Z.U., Izham M., Ibrahim M., and Bukhari N.I. Medicine utilization and pricing: the findings of a household survey in Malaysia. J Gene Med 3 (2005) 47-61
24. International Study of Asthma and Allergies in Chilldhood (ISAAC) Steering Committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 12 (1998) 315-335
25. Rugayah B. Report on second national health and morbidity survey (1997), Public Health Institute, Ministry of Health p. 94-8
26. Lim T.O., Ding L.M., Zaki M., Suleiman A.B., et al. Distribution of blood glucose in a national sample of Malaysian adults. Med J Malaysia 55 (2000) 65-77
27. Clifton J.A. Administered prices in the context of capitalist development. Contrib Polit Econ 4 (1985)
28. Sarmiento A.Z. Alternate drug pricing policies in the Americas. Health economics and drugs (1995), World Health Organization, Geneva DAP Series No.1. WHO/DAP/95.6
29. Gelders S., Ewen M., Noguchi N., and Laing R. Price, availability and affordability: an international comparison of chronic disease medicines (2006), World Health Organization/Health Action International, Cairo. http://mednet3.who.int/medprices/CHRONIC.pdf Available at:
30. Tripathi S.K., Dey D., and Hazra A. Medicine prices and availability in the state of West Bengal, India (2004). http://www.haiweb.org/medicineprices/surveys/200412IW/survey_report.pdf Available at:
31. Kotwani A. Medicine prices in the state of Rajasthan, India (2004). http://www.haiweb.org/medicineprices/surveys.php Available at:
32. Wickremasinghe R. Evidence, policy and advocacy workshop on medicine prices (2006), World Health Organization and Health Action International, Kandy
33. Piong J. Post conference session on pharmacy education. In: Proc. MPS Pharmacy Scientific Conference, Kuala Lumpur; 13 November 2005.
34. Export markets another growth source for domestic pharmaceuticals. The Star (2003)
35. Balasubramaniam K. Policies and strategies on drug pricing, regulations and international experience (1988), International Organization of Consumers Union, Regional Office for Asia and the Pacific, Penang
36. Vandergrift M., and Kanavos P. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. Health Policy 41 (1997) 241-260
37. What price competitiveness in the drug industry?. Lancet 362 (2003) 257
38. Ng LK. The law of medicinal drug regulating safety, efficacy, quality and pricing. LL.B. thesis. Kuala Lumpur: University of Malaya; 1994. p. 119.
39. Azmi I.M., and Alavi R. TRIPS, patents, technology transfer, foreign direct investment and the pharmaceutical industry in Malaysia. J World Intellect Prop 4 (2001)
40. Mahmood M., and Bukhari N.I. Pharmaceutical management and marketing (2002), Tariq Academy, Faisalabad p.115-44
41. Vogel J.R. Pharmaceutical patents and price controls. Clin Ther 24 (2002)
42. Carey J., and Barrett A. Drug prices: what's fair. Bus Week (10/12/2001). http://www.businessweek.com/magazine/content/01_50/b3761001.htm Available at:
43. An innovative challenge to the pharmaceutical industry. Lancet 360 (2002)
44. Pecoul B., Chirac P., Trouillern P., and Pinel J. Access to essential drugs in poor countries: a lost battle. JAMA 28 (1999)
45. Lopert R., Lang D.L., Hill S.R., and Henry D.A. Differential pricing of drugs: a role for cost-effectiveness analysis. Lancet 359 (2002)
46. Pharmaceutical Price Regulation Scheme. Seventh report to parliament (2003), Department of Health
47. Pharmaceutical price regulation scheme. Discussion paper. Available at: (2003). http://www.dh.gov.uk/assetRoot/04/06/73/32/04067332.PDF
48. Darshni S. Medicine prices being sold at high prices. New Strait Times (09/05/2006)
49. Babar Z.U., Izham M., Ibrahim M., Harpal S., and Bukhari N.I. A survey of medicine prices, availability, affordability and price components in Malaysia using the WHO/HAI methodology (2005), UCSI-USM. http://www.haiweb.org/medicineprices/surveys/200410MY/survey_report.pdf Available at:
50. Awang C., and Zin C. Access to medicine still good. New Strait Times (26/01/2006)
51. Razak A.D. Curing the high-cost syndrome. New Strait Times (11/07/2006). Available at: http://202.144.202.76/new_mps/cfm/localnews_view.cfm?id=874 [accessed 12.07.06]